Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck | Zendy

Susumu Okano | Zendy; Akihiro Homma | Zendy; Naomi Kiyota | Zendy; Makoto Tahara | Zendy; Nobuhiro Hanai | Zendy; Takahiro Asakage | Zendy; Kazuto Matsuura | Zendy; Takenori Ogawa | Zendy; Yuki Saito | Zendy; Daisuke Sano | Zendy; Takeshi Kodaira | Zendy; Atsushi Motegi | Zendy; Kôichi Yasuda | Zendy; Shunji Takahashi | Zendy; Kaoru Tanaka | Zendy; Takuma Onoe | Zendy; Tomoya Yokota | Zendy; Yoshinori Imamura | Zendy; Yosuke Ariizumi | Zendy; Tetsuo Akimoto | Zendy; Ryuichi Hayashi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck

Author(s) -

Susumu Okano,

Akihiro Homma,

Naomi Kiyota,

Makoto Tahara,

Nobuhiro Hanai,

Takahiro Asakage,

Kazuto Matsuura,

Takenori Ogawa,

Yuki Saito,

Daisuke Sano,

Takeshi Kodaira,

Atsushi Motegi,

Kôichi Yasuda,

Shunji Takahashi,

Kaoru Tanaka,

Takuma Onoe,

Tomoya Yokota,

Yoshinori Imamura,

Yosuke Ariizumi,

Tetsuo Akimoto,

Ryuichi Hayashi

Publication year - 2020

Publication title -

japanese journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.768

H-Index - 85

eISSN - 1465-3621

pISSN - 0368-2811

DOI - 10.1093/jjco/hyaa220

Subject(s) - medicine , induction chemotherapy , docetaxel , chemotherapy , radiation therapy , oncology , regimen , head and neck squamous cell carcinoma , larynx , cisplatin , clinical trial , head and neck cancer , surgery

In order to maximize the benefit of induction chemotherapy, practice based on a comprehensive interpretation of a large number of clinical trials, as in this review, is essential. The standard treatment for locally advanced squamous cell carcinoma of the head and neck is surgery or chemoradiation. However, induction chemotherapy followed by (chemo) radiotherapy may be used in some circumstances. Although many clinical trials of induction chemotherapy have been conducted, a rationale other than to preserve the larynx is still controversial. Selection of this modality should therefore be made with care. The current standard regimen for induction chemotherapy is docetaxel, cisplatin and 5-FU, but concerns remain about toxicity, cost and the duration of treatment. Regarding treatment after induction chemotherapy, it is also unclear whether radiation alone or chemoradiation is the better option. Furthermore, there is no answer as to what drugs should be used in combination with radiation therapy after induction chemotherapy. Several new induction chemotherapy treatment developments are currently underway, and future developments are expected. This review article summarizes the current position of induction chemotherapy for head and neck squamous cell carcinoma, based on the evidence produced to date, and discusses the future prospects for this treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research